HC
REGN icon

Henshaw Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Henshaw Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-608
Closed -$210K – 312
2018
Q2 		$210K Buy
+608
New +$190K 0.02% 292

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Henshaw Capital's REGN Position: Q3 2018 in Review

Henshaw Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 608 shares — an estimated $210K sold.

Henshaw Capital first reported a position in REGN in Q2 2018 and held it in 1 quarter. The position peaked at $210K in Q2 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

  • Henshaw Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Henshaw Capital sold 608 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $210K.
  • Henshaw Capital first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Henshaw Capital's Regeneron Pharmaceuticals position peaked at $210K in Q2 2018.
  • 644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Henshaw Capital's 13F filing for Q3 2018, filed 28 May 2026.